Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV.

Transplantation

Division of Infectious Diseases, Department of Transplant Services, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI 02903, USA.

Published: November 2008

Transplant physicians and surgeons are familiar with the risks, clinical behavior, and management of cytomegalovirus in transplant recipients. Donor-transmitted viral infections are uncommon but in recent years have brought to light the clinical manifestations of rabies, West Nile virus, and lymphocytic choriomeningitis virus in the early posttransplant period. Later posttransplant, infection with viruses circulating in the community can occur with a number of pathogens, including some vaccine-preventable illnesses such as measles and mumps. Recent advances in molecular microbiology have made it possible to diagnose a growing number of community-acquired viral pathogens infecting transplant recipients. This article reviews some of the emerging and reemerging viral pathogens infecting solid organ and hematopoietic stem-cell recipients, including adenovirus, bocavirus, coronavirus, human herpesvirus-6, lymphocytic choriomeningitis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respiratory syncytial virus, and West Nile virus.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0b013e31818b6548DOI Listing

Publication Analysis

Top Keywords

transplant recipients
8
west nile
8
nile virus
8
lymphocytic choriomeningitis
8
choriomeningitis virus
8
measles mumps
8
viral pathogens
8
pathogens infecting
8
virus
5
emerging viruses
4

Similar Publications

Background: Enhanced recovery after surgery (ERAS) protocols have gained widespread acceptance as a means to enhance surgical outcomes. However, the intricate care required for kidney transplant recipients has not yet led to the establishment of a universally recognized and dependable ERAS protocol for kidney transplantation.

Objective: We devised a customized ERAS protocol to determine its effectiveness in improving surgical and postoperative outcomes among kidney transplant recipients.

View Article and Find Full Text PDF

Background: Early posttransplant cytomegalovirus (CMV) infections in CMV seronegative solid organ transplant recipients (SOTR) with CMV seronegative donors (D-/R-) are often attributed transfusion-transmitted CMV. The prevalence of false-negative donor CMV serology in D-/R- SOTR with early CMV infections has not been explored.

Methods: We determined the frequency and characteristics of CMV DNAemia that occurred within 90 days of transplant among adult SOTR classified as D-/R- who underwent a first SOT at a single center between February 25, 2014 and February 25, 2024.

View Article and Find Full Text PDF

Psychological evaluation of candidates for the uterus transplantation French trial.

Acta Obstet Gynecol Scand

December 2024

Department of Obstetrics, Gynecology and Reproductive Medicine, Foch Hospital, Suresnes, France.

Introduction: Since 2017, women with absolute uterine infertility due to Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome have been eligible to participate in a uterine transplantation clinical trial conducted by Foch Hospital in France. The aim of this study is to assess the psychological state of potential candidates, including recipients, their partners, and their living-related donors.

Material And Methods: Sixteen potential uterus transplant candidates, including recipients, partners, and living-related donors, participated in the study.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to evaluate the correlation between longitudinal monitoring of donor-derived cell free DNA (dd-cfDNA) in lung transplant recipients and a "gold standard" of existing tools (pulmonary function testing, radiographic imaging, laboratory and bronchoscopy data, clinical judgment) to assess allograft function.

Methods: 24 consecutive transplant recipients were prospectively enrolled in this study measuring dd-cfDNA levels monthly in the first year after bilateral lung transplant. Blinded clinical adjudications were performed at the same timepoints to categorize allograft function as stable (FEV1 within 10% of prior value or when compared to best two averaged post-transplant values) or unstable.

View Article and Find Full Text PDF

Objective: Cardiac Allograft Vasculopathy (CAV), a process of vascular damage accelerated by antibody-mediated rejection (AMR), is one of the leading causes of cardiac transplant failure. Proteasome inhibitors (PIs) are utilized to treat AMR, however PI-associated toxicity limits their therapeutic utility. Novel immunoproteasome inhibitors (IPIs) have higher specificity for immune cells and have not been investigated for AMR in cardiac transplant patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!